Semaglutide 5mg/2ml dosage chart: reading the numbers on your pen

What 5mg/2ml actually tells you, and what it doesn't

The label on a Wegovy pen packs a lot into a small space. For the 5mg/2ml presentation, the first number is the total quantity of semaglutide in the cartridge; the second is the volume of liquid it is dissolved in. Dividing those gives you the concentration: 2.5mg per ml. That matters because the pen mechanism delivers a fixed volume per injection, and it is that fixed volume (not a dial you turn) that determines how many milligrams you receive each week.

One practical check worth doing when a new pen arrives: confirm the label reads 5mg/2ml and that the solution in the cartridge appears clear and colourless. A cloudy, discoloured or particle-containing cartridge should never be used; contact your pharmacy or prescriber before proceeding. That takes about twenty seconds and could catch a storage problem before it becomes a safety one.

What the concentration label does not tell you is where you should be in your dosing schedule. That is a clinical judgement. The full semaglutide dosage chart maps out how the schedule progresses from the initial 0.25mg pen through to the higher maintenance doses, and seeing it in context makes the individual pen label easier to interpret, including how the quantities scale up at each stage, which you can explore further in the 10mg semaglutide dosage chart for the upper end of the range. For guidance on your personal schedule, your prescriber is the right person to ask.

Where the 5mg/2ml pen sits in the Wegovy titration ladder

Wegovy is not a single-dose treatment. The UK-licensed approach begins at a low weekly dose, with each increase happening roughly every four weeks as tolerability allows. The Wegovy dose progression moves through a series of pen strengths, 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg are the steps leading to the standard maintenance dose, with 7.2mg now also approved by the MHRA for eligible patients.

The 5mg/2ml presentation is a mid-range pen in that sequence. Its job is to bridge patients between the lower starter doses and the higher maintenance doses, at a concentration that keeps injection volumes clinically manageable. Switching from one pen strength to another always reflects a prescriber's decision about where you are in the programme, based on your response and tolerance so far.

It is also worth being clear about what this pen is not: Rybelsus tablets are also oral semaglutide but carry different strengths and are licensed for type 2 diabetes, not weight management. The 5mg/2ml Wegovy pen and the 14mg Rybelsus tablet are different products for different conditions. The Wegovy overview sets out the licensed indications and what to expect from the injectable form.

The decision your prescriber is making on your behalf

SK3 framing matters here: when you look at a dosage chart, the underlying question you are probably trying to answer is whether you are at the right dose, whether you should move up, or whether something has changed. That decision has several moving parts. How well you tolerated the previous pen. Whether you have reached the four-week minimum at the current strength. Whether any side effects have settled. Whether your weight trajectory so far supports continuing as planned.

None of those factors appear on a dosage chart. They are exactly what a prescriber reviews before approving a dose increase. At nume, that review happens for every repeat, a named clinician reads your update before your next pen is dispensed, rather than the process running on autopilot. For an overview of how dose decisions are made across the semaglutide schedule, that page covers the clinical reasoning behind each step.

The cost of Wegovy treatment varies by dose and provider; higher-dose pens typically carry a higher price, which is another reason to understand what strength you are actually receiving. A prescription is the only lawful route to any of these pens in the UK, and the NHS patient information for semaglutide, published on the NHS medicines pages, is the authoritative reference for storage, administration and what to do if you miss a dose.

When the chart is not enough, and what to do

Dosage charts are useful reference tools. They become less useful (and occasionally misleading) when they are used to self-adjust a schedule that a prescriber has not reviewed, or when they are sourced from settings outside the UK where different pen concentrations or brand names apply. Zepbound, for example, is the US brand of tirzepatide and does not exist as a UK product; charts or guides referencing it are not applicable here.

If you are mid-schedule and unsure whether the 5mg/2ml pen is the right next step, the right move is to raise it with your prescriber before injecting. The same applies if a pen looks different from previous ones, arrived outside its cold-chain packaging, or if you have had a health change since your last review. Suspected side effects, including anything unexpected or severe, can and should be reported via the MHRA Yellow Card scheme, which is open to patients as well as healthcare professionals.

If you are still working out whether semaglutide is right for you and what the starting process looks like, the weight-loss treatments page outlines how a clinical consultation works and what our prescribers assess before a pen is prescribed.